Edition:
United States

Advanced Accelerator Applications SA (AAAP.OQ)

AAAP.OQ on NASDAQ Stock Exchange Global Select Market

81.63USD
9 Feb 2018
Change (% chg)

-- (--)
Prev Close
$81.63
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
132,052
52-wk High
$82.74
52-wk Low
$35.17

Select another date:

Mon, Feb 12 2018

BRIEF-Advanced Accelerator Applications Enters Into Worldwide License Agreement With Cancer Targeted Technology

* ADVANCED ACCELERATOR APPLICATIONS SA - ENTERED INTO EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH CANCER TARGETED TECHNOLOGY

BRIEF-Advanced Accelerator Applications To Withdraw ADSs From Nasdaq Global Select Market​

* ADVANCED ACCELERATOR APPLICATIONS SA - ‍NOTIFIED NASDAQ STOCK MARKET OF ITS DETERMINATION TO WITHDRAW ADSS FROM LISTING ON NASDAQ GLOBAL SELECT MARKET​

BRIEF-Advanced Accelerator Applications Announces Commencement Of Novartis Tender Offer

* ADVANCED ACCELERATOR APPLICATIONS ANNOUNCES COMMENCEMENT OF NOVARTIS TENDER OFFER

BRIEF-Advanced Accelerator Applications Board Recommends $3.9 Bln All Cash Tender Offer By Novartis

* ADVANCED ACCELERATOR APPLICATIONS BOARD OF DIRECTORS RECOMMENDS $3.9 BILLION ALL CASH TENDER OFFER BY NOVARTIS

BRIEF-Advanced Accelerator Applications reports qtrly loss per share EUR​ ‍0.26

* Advanced Accelerator Applications reports 39% sales growth for third quarter 2017

Novartis to buy French cancer specialist AAA for $3.9 billion

ZURICH Novartis has agreed to buy French-based Advanced Accelerator Applications (AAA) for $3.9 billion, giving it a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs.

UPDATE 3-Novartis to buy French cancer specialist AAA for $3.9 bln

* French company had first-half sales of $78 mln (Adds Breakingviews link, further detail on Novartis cancer drugs)

BRIEF-Advanced Accelerator announces $3.9 bln all cash proposed tender offer by Novartis

* Advanced accelerator applications announces $3.9 billion all cash proposed tender offer by Novartis

BRIEF-Advanced Accelerator announces European approval of lutetium oxodotreotide for gastroenteropancreatic neuroendocrine tumors

* Advanced Accelerator Applications announces European approval of lutetium (177lu) oxodotreotide (lutathera®) for gastroenteropancreatic neuroendocrine (gep-net) tumors

U.S. average retail gasoline price rises to $2.59/gallon: AAA

NEW YORK Retail U.S. gasoline prices rose to $2.59 a gallon on Saturday in the wake of Hurricane Harvey, according to motorists advocacy group AAA.

Select another date: